LigoCyte Pharmaceuticals of Bozeman, Montana Receives $4.6M NIH Biodefense Challenge Grant for Intranasal Anthrax Vaccine

LigoCyte Pharmaceuticals announced today that they have been awarded a $4.6M challenge grant from the National Institutes of Health (NIH) for the preclinical advancement of their unique, intranasal vaccine against anthrax.

"Securing this level of a competitive NIH award validates our anthrax vaccine approach and allows us to quickly move forward in our preclinical development," said Dr. Charles Richardson, LigoCyte’s Senior VP of Research and Development. "This funding demonstrates the value of our ongoing Department of Defense (DOD) appropriations in the early development of novel biodefense vaccines."

LigoCyte’s vaccine programs, aimed against potential agents of biowarfare, continue to be funded by the DOD through appropriations supported by Senator Conrad Burns (R-MT).

Full Story:

Posted in:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.